Abstract
Background
Case reports suggest lacosamide may have a role in status epilepticus (SE). The purpose of this case series is to describe the use of lacosamide in refractory SE (RSE) at our institution.
Methods
Observational study of all patients admitted to the neurosciences intensive care unit with RSE who received at least one dose of lacosamide from October 2009 to September 2010.
Results
Nine patients received lacosamide after failure of at least two other agents. Lacosamide was started a median of 2 days (range: 0–14 days) after the onset of SE. The most frequently used dosing regimen was an initial intravenous dose of 200 mg followed by 200 mg every 12 h. Most patients had received 3 (range: 2–5) AEDs prior to lacosamide. Levetiracetam was used prior to lacosamide in all cases. No patients evaluated responded to lacosamide according to our predefined criteria. One patient developed angioedema after receiving two doses; another patient developed angioedema where timing in relation to the lacosamide was unclear. Care was withdrawn in three of the nine patients for reasons unrelated to lacosamide. Lacosamide was continued at discharge on all surviving patients except in one case of angioedema.
Conclusions
This is the largest case series to date describing the use of lacosamide in patients with RSE. Despite the novel mechanism of action, we observed no evidence that lacosamide is effective in RSE; however, our sample size was small. Further study is needed to determine the role of lacosamide in SE, especially early in the treatment course.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marik PE, Varon J. The management of status epilepticus. Chest. 2004;126:582–91.
Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay E, Mamdani MB. A comparison of four treatments for generalized convulsive status epilepticus. N Eng J Med. 1998;339:792–8.
Cross SA, Curran MP. Lacosamide in partial-onset seizures. Drugs. 2009;69(4):449–59.
Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(7):1308–17.
Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50(3):443–53.
Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia. 2010;51(2):316–7.
Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009;14:429–31.
Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555–68.
Ji T, Zubkov AY, Wijdicks EFM, Manno EM, Rabinstein AA, Kotagal S. Massive tongue swelling in refractory status epilepticus treated with high-dose pentobarbital. Neurocrit Care. 2009;10:73–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goodwin, H., Hinson, H.E., Shermock, K.M. et al. The Use of Lacosamide in Refractory Status Epilepticus. Neurocrit Care 14, 348–353 (2011). https://doi.org/10.1007/s12028-010-9501-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12028-010-9501-8